XM Therapeutics
Chris Bowley has extensive experience in biomedical engineering and product development, currently serving as Head of Operations at Flourish Collective Incorporated and Principal at NextWave Medtech Solutions since 2020 and 2022, respectively. Chris holds the position of Director of Product Development at XM Therapeutics and previously worked as Associate Director of Program Management at Beta Bionics, overseeing the iLet Duo Bionic Pancreas program. With a strong background in R&D management, Chris has led significant initiatives at BVI Medical and BD, including the development of surgical biomaterials and novel medical devices. Chris's expertise encompasses product development strategy, program management, and innovation in the medtech sector, underpinned by a Bachelor's degree in Biomedical Engineering from Case Western Reserve University.
This person is not in any teams
This person is not in any offices
XM Therapeutics
The Extracellular Matrix (ECM) - the scaffolding material that organizes cells into tissues and organs - is a proactive participant in chronic disorders enabling continued inflammation, fibrosis and ischemia. Spun off from Brown University in 2022, XM Therapeutics is developing a platform technology to directly modulate the dysfunctional ECM to improve tissue function and enable organ repair. We generate injectable, acellular designer ECM Particles sourced from human 3D cell cultures. Our initial focus is on cardiovascular and pulmonary indications with significant additional potential in other diseases. We are a Providence, RI - based seed stage start-up with a clear mission: to improve the health status of patients with chronic disorders by modulating and repairing the dysfunctional Extracellular Matrix.